Program: Tuesday (25.10.2016)

07:30 – 08:30

Satellite Symposium (by Bristol-Myers Squibb) Ask the Expert: An Open Forum on Hodgkin Lymphoma

  • Philippe Armand
  • 07:30–07:50

    Panelists

    • Craig H. Moskowitz
    • Graham Collins
    • Catherine Diefenbach
    • Vincent Ribrag

08:30 – 10:00

Scientific Session Pediatric HL

  • Christine Mauz-KΓΆrholz
  • Nelson Spector
  • 08:30–08:50

    Interim results of EuroNet-PHL-C1

    • Judith Landman-Parker
  • 08:50–09:10

    Targeted agents in pediatric HL

    • Monika Metzger
  • 09:10–09:30

    COG / ECOG: AYA HL

    • Kara Kelly
  • 09:30–09:40

    Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/ A12707)

    • Stephen Daw
  • 09:40–09:50

    Phase III ABC study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children's Oncology Group

    • Kara Kelly
  • 09:50–10:00

    Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis

    • Andrew Evens

10:30 – 12:00

Scientific Session Advanced Stages

  • Massimo Federico
  • Volker Diehl
  • 10:30–11:10

    Debate: PET-guided ABVD versus old school BEACOPP

    • Anton Hagenbeek
    • Peter Johnson
    • Peter Borchmann
  • 11:10–11:30

    Perspectives in advanced HL

    • Pauline Brice
  • 11:30–11:40

    BEACOPPescalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials

    • Bastian von Tresckow
  • 11:40–11:50

    Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials

    • Marc AndrΓ©
  • 11:50–12:00

    Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging,

    • Jonathan Friedberg

12:15 – 13:00

Satellite Symposium (by Roche Pharma AG) Classification of New Therapeutic Options for CLL and Follicular NHL

  • Kai HΓΌbel
  • 12:15–12:35

    Chronic Lymphocytic Leukemia

    • Clemens Wendtner
  • 12:35–13:00

    Relapsed Follicular Non-Hodgkin Lymphoma

    • Kai HΓΌbel

13:00 – 13:45

Main Program Poster Walk

14:00 – 15:30

Scientific Session Relapsed HL

  • Pauline Brice
  • Andreas Engert
  • 14:00–14:20

    Brentuximab vedotin in relapsed HL

    • Craig H. Moskowitz
  • 14:20–14:40

    Clinical results with anti-PD(L)1 antibodies in HL

    • Philippe Armand
  • 14:40–15:00

    Role of allo-Tx in the PD1 era

    • Franck Morschhauser
  • 15:00–15:10

    CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation

    • Pier Luigi Zinzani
  • 15:10–15:20

    Pembrolizumab for relapsed / refractory classical Hodgkin Lymphoma (R / R cHL): multicohort, phase 2 KEYNOTE-087 study

    • Craig H. Moskowitz
  • 15:20–15:30

    TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed / refractory Hodgkin Lymphoma (HL). A phase 1 dose- escalation study

    • Anton Hagenbeek

16:00 – 17:30

Scientific Session Survivorship

  • Flora van Leeuwen
  • Peter Borchmann
  • 16:00–16:20

    Fatigue

    • Steffanie Kreissl
  • 16:20–16:40

    Survivorship surveillance

    • Alexander Fossa
  • 16:40–17:00

    Second malignancies

    • Flora van Leeuwen
  • 17:00–17:10

    Patient preferences – survey of HL survivors on treatment associated burdens and side effects

    • Carolin BΓΌrkle
  • 17:10–17:20

    Change in peripheral blood lymphocyte telomere length in relation to mortality and morbidity in Hodgkin Lymphoma patients

    • Radhia M'kacher
  • 17:20–17:30

    The impact of treatment type and age on ovarian toxicity in the RATHL study

    • RA Anderson

17:45

Scientific Session Closing Remarks

  • Andreas Engert

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.